Dual-targeting anti-angiogenic cyclic peptides as potential drug leads for cancer therapy

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Chan, Lai Yue ^a   Craik, David J ^a   Daly, Norelle L ^b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b JAMES COOK UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; CYCLOPEPTIDE; CYCLOTIDE; EPITOPE; MELITTIN; TRYPSIN; TRYPSIN INHIBITOR MCOTI-II;

ANIMAL; CELL MOTION; CELL PROLIFERATION; CHEMISTRY; CHORIOALLANTOIS; CYTOLOGY; DRUG DESIGN; DRUG EFFECT; DRUG SCREENING; ERYTHROCYTE; HEMOLYSIS; HUMAN; IC50; MOMORDICA; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; QUAIL; SIGNAL TRANSDUCTION; UMBILICAL VEIN ENDOTHELIAL CELL;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL MOVEMENT; CELL PROLIFERATION; CHORIOALLANTOIC MEMBRANE; CYCLOTIDES; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; EPITOPES; ERYTHROCYTES; HEMOLYSIS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INHIBITORY CONCENTRATION 50; MAGNETIC RESONANCE SPECTROSCOPY; MELITTEN; MOMORDICA; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDES, CYCLIC; QUAIL; SIGNAL TRANSDUCTION; TRYPSIN;

EID: 84991665874     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep35347     Document Type: Article

References (49)

1. Carmeliet, P. & Jain, R. K. Angiogenesis in cancer and other diseases. Nature 407, 249-257 (2000).
2. Singh, M. & Ferrara, N. Modeling and predicting clinical efficacy for drugs targeting the tumor milieu. Nat. Biotechnol. 30, 648-657 (2012).
3. Shojaei, F. Anti-angiogenesis therapy in cancer: current challenges and future perspectives. Cancer Lett. 320, 130-137 (2012).
4. Thornton, A. D., Ravn, P., Winslet, M. & Chester, K. Angiogenesis inhibition with bevacizumab and the surgical management of colorectal cancer. Br. J. Surg. 93, 1456-1463 (2006).
5. Chua, T. C. Gastrointestinal oncological surgery in patients with metastatic cancer treated with angiogenesis inhibitors: safe or not? ANZ J. Surg. 79, 672-673 (2009).
6. Otvos, L. Jr. & Wade, J. D. Current challenges in peptide-based drug discovery. Front. Chem. 2, 62 (2014).
7. Craik, D. J., Fairlie, D. P., Liras, S. & Price, D. The future of peptide-based drugs. Chem. Biol. Drug Des. 81, 136-147 (2013).
8. Reynolds, A. R. et al. Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors. Nat. Med. 15, 392-400 (2009).
9. Craik, D. J., Daly, N. L., Bond, T. & Waine, C. Plant cyclotides: a unique family of cyclic and knotted proteins that defines the cyclic cystine knot structural motif. J. Mol. Biol. 294, 1327-1336 (1999).
10. Hernandez, J. F. et al. Squash trypsin inhibitors from Momordica cochinchinensis exhibit an atypical macrocyclic structure. Biochemistry 39, 5722-5730 (2000).
11. Luckett, S. et al. High-resolution structure of a potent, cyclic proteinase inhibitor from sunflower seeds. J. Mol. Biol. 290, 525-533 (1999).
12. Craik, D. J. Joseph Rudinger memorial lecture: discovery and applications of cyclotides. J. Pept. Sci. 19, 393-407 (2013).
13. Saether, O. et al. Elucidation of the primary and three-dimensional structure of the uterotonic polypeptide kalata B1. Biochemistry 34, 4147-4158 (1995).
14. Clark, R. J., Daly, N. L. & Craik, D. J. Structural plasticity of the cyclic-cystine-knot framework: implications for biological activity and drug design. Biochem. J. 394, 85-93 (2006).
15. Poth, A. G., Chan, L. Y. & Craik, D. J. Cyclotides as grafting frameworks for protein engineering and drug design applications. Biopolymers 100, 480-491 (2013).
16. Northfield, S. E. et al. Disulfide-rich macrocyclic peptides as templates in drug design. Eur. J. Med. Chem. 77, 248-257 (2014).
17. Wong, C. T. et al. Orally active peptidic bradykinin B1 receptor antagonists engineered from a cyclotide scaffold for inflammatory pain treatment. Angew. Chem. Int. Ed. Engl. 51, 5620-5624 (2012).
18. Chan, L. Y. et al. Engineering pro-angiogenic peptides using stable, disulfide-rich cyclic scaffolds. Blood 118, 6709-6717 (2011).
19. Ji, Y. et al. In vivo activation of the p53 tumor suppressor pathway by an engineered cyclotide. J. Am. Chem. Soc. 135, 11623-11633 (2013).
20. Gunasekera, S. et al. Engineering stabilized vascular endothelial growth factor-A antagonists: synthesis, structural characterization, and bioactivity of grafted analogues of cyclotides. J. Med. Chem. 51, 7697-7704 (2008).
21. Welti, J., Loges, S., Dimmeler, S. & Carmeliet, P. Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. J. Clin. Invest. 123, 3190-3200 (2013).
22. Suich, D. J. et al. Template-constrained cyclic peptide analogues of somatostatin: subtype-selective binding to somatostatin receptors and antiangiogenic activity. Bioorg. Med. Chem. 8, 2229-2241 (2000).
23. Wright, R. M. et al. Binding epitope of somatostatin defined by phage-displayed peptide libraries. Biotechnology 13, 165-169 (1995).
24. Abe, R. et al. Topical application of anti-angiogenic peptides based on pigment epithelium-derived factor can improve psoriasis. J. Dermatol. Sci. 57, 183-191 (2010).
25. Dawson, D. W. et al. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 285, 245-248 (1999).
26. Maik-Rachline, G. & Seger, R. Variable phosphorylation states of pigment-epithelium-derived factor differentially regulate its function. Blood 107, 2745-2752 (2006).
27. Bae, D. G., Gho, Y. S., Yoon, W. H. & Chae, C. B. Arginine-rich anti-vascular endothelial growth factor peptides inhibit tumor growth and metastasis by blocking angiogenesis. J. Biol. Chem. 275, 13588-13596 (2000).
28. Yoo, S. A. et al. Arginine-rich anti-vascular endothelial growth factor (anti-VEGF) hexapeptide inhibits collagen-induced arthritis and VEGF-stimulated productions of TNF-alpha and IL-6 by human monocytes. J. Immunol. 174, 5846-5855 (2005).
29. Podar, K. & Anderson, K. C. The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. Blood 105, 1383-1395 (2005).
30. Weis, S. M. & Cheresh, D. A. alphaV integrins in angiogenesis and cancer. Cold Spring Harb. Perspect. Med. 1, a006478 (2011).
31. Adams, R. L., Adams, I. P., Lindow, S. W., Zhong, W. & Atkin, S. L. Somatostatin receptors 2 and 5 are preferentially expressed in proliferating endothelium. Br. J. Cancer 92, 1493-1498 (2005).
32. Atkins, M., Jones, C. A. & Kirkpatrick, P. Sunitinib maleate. Nat. Rev. Drug Discov. 5, 279-280 (2006).
33. Fosgerau, K. & Hoffmann, T. Peptide therapeutics: current status and future directions. Drug Discov. Today 20, 122-128 (2015).
34. Ovadia, O. et al. Improvement of drug-like properties of peptides: the somatostatin paradigm. Expert Opin. Drug Discov. 5, 655-671 (2010).
35. Li, H. et al. Triazine-based tool box for developing peptidic PET imaging probes: syntheses, microfluidic radiolabeling, and structure-activity evaluation. Bioconjug. Chem. 25, 761-772 (2014).
36. Gibbons, D. L. & Byers, L. A. A. HER 1-2 punch: dual EGFR targeting deals resistance a deadly blow. Cancer Discov. 4, 991-994 (2014).
37. Conibear, A. C. et al. The cyclic cystine ladder of theta-defensins as a stable, bifunctional scaffold: a proof-of-concept study using the integrin-binding RGD motif. ChemBioChem 15, 451-459 (2014).
38. Huang, Y. H. et al. Design of substrate-based BCR-ABL kinase inhibitors using the cyclotide scaffold. Sci. Rep. 5, 12974 (2015).
39. Sun, L. C. & Coy, D. H. Somatostatin receptor-targeted anti-cancer therapy. Curr. Drug Deliv. 8, 2-10 (2011).
40. Craword, S. E., Fitchev, P., Veliceasa, D. & Volpert, O. V. The many facets of PEDF in drug discovery and disease: a diamond in the rough or split personality disorder? Expert Opin. Drug Discov. 8, 769-792 (2013).
41. Rai, U., Thrimawithana, T. R., Valery, C. & Young, S. A. Therapeutic uses of somatostatin and its analogues: current view and potential applications. Pharmacol. Ther. 152, 98-110 (2015).
42. Becerra, S. P. & Notario, V. The effects of PEDF on cancer biology: mechanisms of action and therapeutic potential. Nat. Rev. Cancer 13, 258-271 (2013).
43. Zhang, K., Zhang, L. & Weinreb, R. N. Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma. Nat. Rev. Drug Discov. 11, 541-559 (2012).
44. Chan, L. Y. et al. Isolation and characterization of peptides from Momordica cochinchinensis seeds. J. Nat. Prod. 72, 1453-1458 (2009).
45. Chan, L. Y., Craik, D. J. & Daly, N. L. Cyclic thrombospondin-1 mimetics: grafting of a thrombospondin sequence into circular disulfide-rich frameworks to inhibit endothelial cell migration. Biosci. Rep. 35, e00270 (2015).
46. Vranken, W. F. et al. The CCPN data model for NMR spectroscopy: development of a software pipeline. Proteins 59, 687-696 (2005).
47. Wuthrich, K. NMR of Proteins and Nucleic Acids (Wiley-Interscience, 1986).
48. Wishart, D. S. et al. 1H, 13C and 15N chemical shift referencing in biomolecular NMR. J. Biomol. NMR 6, 135-140 (1995).
49. Koradi, R., Billeter, M. & Wuthrich, K. MOLMOL: a program for display and analysis of macromolecular structures. J. Mol. Graph. 14, 51-55, 29-32 (1996).